To further validate the above observation and assess the contribution of released extracellular HMGB1 on tumour growth, we next treated mice implanted subcutaneously with lamin-shRNA-transduced B16 cells with either a recombinant HMGB1 inhibitor (BoxA, 50 μg i.p. every 3 days) or vehicle (PBS) in an independent set of in vivo experiments. This evidence concerns the gene HMGB1 and neoplasm.